Trialssemaglutidechia tai tianqingwegovyobesitychina

Chia Tai Tianqing completes phase 3 of semaglutide biosimilar against Wegovy

The open-label Chinese study randomized 408 obese adults with BMI at or above 28 to TQF3510 or Wegovy, with percent weight loss at 44 weeks as the primary endpoint.

By Priya Raman · Science Reporter

Sep 25 08:00 ETSource: ClinicalTrials.gov

The wire

01The multicenter randomized phase 3 began March 20, 2025 and enrolled 408 subjects, 204 per arm, testing equivalence within a margin of plus or minus 4.16% for percent weight change at 44 weeks.
02A completed head-to-head against Wegovy signals a domestic Chinese semaglutide entrant as Novo Nordisk's compound patent protection in China lapses, with pricing implications for the region.
03The registry lists the study as completed but no results are posted; the design is open-label and the equivalence threshold was derived from a meta-analysis of Wegovy registration studies.

From the source

A Clinical Study Comparing Semaglutide Injection and Wegovy® for Weight Management in Obese Subjects
NCT06738979 · PHASE3 · COMPLETED · Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Conditions: Obesity.

Read at clinicaltrials.gov

Source URL https://clinicaltrials.gov/study/NCT06738979